news

Our latest
Press Releases & Updates

Latest press releases

RetinAI and Geographic Atrophy (GA) Expert Working Group partner to enable data collaboration and automated analysis of GA biomarkers for CAM using Discovery

RetinAI partnered with the Classification of Atrophy Meeting (CAM) Group in December 2022 to provide RetinAI’s Discovery® platform to the expert working group, consisting of more than 30 members, to facilitate peer-to-peer data collaboration and perform accelerated, automated biomarker analysis of real-world datasets of geographic atrophy (GA) patients. 

RetinAI’s technology accelerated large-scale analysis of fluid dynamics in a Real-World, neovascular Age-related Macular Degeneration (nAMD) national database

RetinAI is proud to have provided its CE-marked AI tools for fluid quantification to support the analysis in a large scale, multicenter, real-world national database of neovascular Age related Macular Degeneration (nAMD) patients. The results of the study, recently published in the British Journal of Ophthalmology, demonstrate that volumetric measures derived from AI-based segmentation of OCT volumes provide useful information for clinicians to consult their patients at diagnosis.

RetinAI launches Discovery CORE™: an AI-powered, collaborative platform to accelerate Clinical & Academic Research, & RWE analysis in ophthalmology

RetinAI is proud to launch Discovery CORE™ with AI for retinal fluid and layer segmentation. Discovery CORE and its AI models have been designed to accelerate data analysis and help clinical and academic researchers collaborate more efficiently, in real time, with their peers, on medical and imaging datasets. Automatically and in an instant, the software measures retinal fluid volumes and retinal layer thickness across OCT datasets. With built-in annotation tools and electronic case report forms, new data insights can also be collected across peer networks, keeping the information digitized, centralized and secure.

RetinAI will attend AAO 2022 & is excited to introduce advances in AI for GA analysis & Progression Prediction & Discovery CORE™

RetinAI is a leader in clinical and imaging data management software and advanced analytics for Ophthalmology. The company’s platform technology and AI improve workflows in research, clinical studies and bring precision medicine applications to pharma, clinical research organizations (CROs) and clinicians.

Latest updates

Machine learning can predict anti-VEGF treatment demand in a Treat-and-Extend regimen for patients with nAMD, DME and RVO associated ME

2 new Posters in ARVO 2021 Virtual

We are very excited of our team and collaborators presenting 2 posters in ARVO 2021! One Poster on 'Longitudinal analysis of Retinal Pigment Epithelium Atrophy progression using an automated segmentation algorithm' providing segmentation analysis over 5 years using deep learning,
and a poster on 'Automated fovea and optic disc detection in the presence of occlusions in Fundus SLO Images'.

New publication on TVST - Automated quantification of pathological fluids in neovascular age-related degeneration, and it's repeatability using deep learning

In this peer reviewed publication, we develop a reliable algorithm for the automated identification, localization, and volume measurement of exudative manifestations in neovascular age-related macular degeneration (nAMD), including intraretinal (IRF), subretinal fluid (SRF), and pigment epithelium detachment (PED), using a deep-learning approach. The deep-learning algorithm can simultaneously acquire a high level of performance for the identification and volume measurements of IRF, SRF, and PED in nAMD, providing accurate and repeatable predictions. Including layer segmentation during training and squeeze-excite block in the network architecture were shown to boost the performance. Source: Mantel et al. , TVST 2021, 10 (17) - https://doi.org/10.1167/tvst.10.4.17 Authors: Irmela Mantel; Agata Mosinska; Ciara Bergin; Maria Sole Polito; Jacopo Guidotti; Stefanos Apostolopoulos; Carlos Ciller; Sandro De Zanet

Translation Vision Science and Technology

RetinAI receives ISO 13485:2016 certification

Retinai has just received the ISO 13485 certification, a recognition awarded by regulatory bodies and necessary for companies willing to develop & commercialise Medical Devices. RetinAI Discovery, our platform for medical image and data management in ophthalmology, is now getting ready to be commercialised to clinics as a medical device. We are extremely proud of the team for achieving the certification!

Contact us for more informations! We are happy to hear from you!